SCMP Share Price

Open 15.80 Change Price %
High 16.05 1 Day -0.35 -2.22
Low 15.35 1 Week -0.70 -4.33
Close 15.45 1 Month 4.10 36.12
Volume 587072 1 Year -1.25 -7.49
52 Week High 18.75
52 Week Low 0.00
SCMP Important Levels
Resistance 2 16.10
Resistance 1 15.83
Pivot 15.62
Support 1 15.07
Support 2 14.80
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.70 0.20%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
RITT 0.06 -45.45%
More..

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP)

SCMP Technical Analysis 3
As on 2nd Dec 2016 SCMP Share Price closed @ 15.45 and we RECOMMEND Buy for LONG-TERM with Stoploss of 12.22 & Buy for SHORT-TERM with Stoploss of 13.48 we also expect STOCK to react on Following IMPORTANT LEVELS.
SCMP Target for December
1st Target up-side 20.04
2nd Target up-side 22.69
3rd Target up-side 25.35
1st Target down-side 12.46
2nd Target down-side 9.81
3rd Target down-side 7.15
SCMP Other Details
Segment EQ
Market Capital 208269664.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.sucampo.com
SCMP Address
SCMP
4520 East-West Highway
3rd Floor
Bethesda, MD 20814
United States
Phone: 301-961-3400
Fax: 301-961-3440
Interactive Technical Analysis Chart Sucampo Pharmaceuticals, Inc. ( SCMP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sucampo Pharmaceuticals, Inc.
SCMP Business Profile
Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company�s prostone-based compounds target the ClC-2 and big potassium (BK), ion channels. It is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other therapeutic applications of its drug technology. The Company�s products include AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl). AMITIZA is marketed in the United States for three gastrointestinal indications: chronic idiopathic constipation (CIC), in adults, irritable bowel syndrome with constipation (IBS-C), in adult women, and opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.